Development of anti-CD47 single-chain Variable Fragment Targeted Magnetic Nanoparticles for Treatment of Human Bladder Cancer

Rezaei, Gashin; Habibi‐Anbouhi, Mahdi; Azadmanesh, Kayhan; Moradi‐Kalbolandi, Shima; Behdani, Mahdi; Ghazizadeh, Leila; Abolhassani, Mohsen; Shokrgozar, Mohammad Ali

doi:10.2217/nnm-2016-0302

Cited by 17 publications

(7 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of the cell surface integrin-associated protein CD47 (ubiquitously expressed on normal cells) is abundantly expressed on most tumor cells and creates a "do-not-eat-me" signal through binding with the signal-regulatory protein alpha (SIRPa) on macrophages (37)(38)(39). SIRPa is a regulatory membrane glycoprotein expressed on the macrophage membrane that accumulates at a phagocytic synapse between macrophages and tumor cells upon CD47 binding (37,40). Thus, the blockade of the CD47-SIRPa interaction by anti-CD47 antibody could restore the macrophagemediated phagocytosis against tumor (Figure 1) (41-43).…”

Section: Mnps For Enhancing Macrophage Anti-tumor Activitymentioning

confidence: 99%

Applications of Magnetite Nanoparticles in Cancer Immunotherapies: Present Hallmarks and Future Perspectives

et al. 2021

View full text Add to dashboard Cite

Current immuno-oncotherapeutic protocols that inhibit tumor immune evasion have demonstrated great clinical success. However, the therapeutic response is limited only to a percentage of patients, and the immune-related adverse events can compromise the therapeutic benefits. Therefore, improving cancer immunotherapeutic approaches that pursue high tumor suppression efficiency and low side effects turn out to be a clinical priority. Novel magnetite nanoparticles (MNPs) exhibit great potential for therapeutic and imaging applications by utilizing their properties of superparamagnetism, good biocompatibility, as well as the easy synthesis and modulation/functionalization. In particular, the MNPs can exert magnetic hyperthermia to induce immunogenic cell death of tumor cells for effective antigen release and presentation, and meanwhile polarize tumor-associated macrophages (TAMs) to M1 phenotype for improved tumor killing capability, thus enhancing the anti-tumor immune effects. Furthermore, immune checkpoint antibodies, immune-stimulating agents, or tumor-targeting agents can be decorated on MNPs, thereby improving their selectivity for the tumor or immune cells by the unique magnetic navigation capability of MNPs to promote the tumor killing immune therapeutics with fewer side effects. This mini-review summarizes the recent progress in MNP-based immuno-oncotherapies, including activation of macrophage, promotion of cytotoxic T lymphocyte (CTL) infiltration within tumors and modulation of immune checkpoint blockade, thus further supporting the applications of MNPs in clinical therapeutic protocols.

show abstract

Section: Mnps For Enhancing Macrophage Anti-tumor Activitymentioning

confidence: 99%

Applications of Magnetite Nanoparticles in Cancer Immunotherapies: Present Hallmarks and Future Perspectives

et al. 2021

View full text Add to dashboard Cite

show abstract

“…[197,[375][376][377][378][379][380][381] Rezaei et al synthesized an anti-CD47 scFv through an immunized antibody phage display library and then conjugated the selected scFvs to magnetic nanoparticles (forming scFv-MNPs). [382] The scFv-MNPs displayed high affinity toward CD47-positive bladder cancer cells, enabling significant inhibition of tumor growth and metastasis in animal models. Besides, Zou et al demonstrated that the NPs functionalized by svFc fragments could be used as theranostic agents for the detection and treatment of pancreatic cancer.…”

Section: Nanoparticles Functionalized By Single-chain Variable Fragme...mentioning

confidence: 99%

Antibody‐Incorporated Nanomedicines for Cancer Therapy

Chen

2022

Advanced Materials

View full text Add to dashboard Cite

show abstract

“…While the wealth of information in terms of production and modification often favors the use of full antibodies for targeting purposes, limitations such as immunogenicity, low stability, rapid elimination, and less than expected efficiency have promoted the generation and use of various antibody fragments [ 287 ]. Within this context, Fab type fragments [ 288 ], single chain variable fragments (scfV) [ 289 ], half-antibodies (hAB) [ 290 ], diabodies [ 291 ], and bispecific antibodies [ 292 ] have been tagged on nanoparticle surface to enhance their specificity for a certain target. Antibody fragments are advantageous over full immunoglobulins in terms of their lower immunogenicity, higher nanoparticle loading due to their smaller size, and better controllability of their orientation on the nanoparticle surface [ 287 ].…”

Section: Active Targetingmentioning

confidence: 99%

Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art

2020

View full text Add to dashboard Cite

Within recent decades, the development of nanotechnology has made a significant contribution to the progress of various fields of study, including the domains of medical and pharmaceutical sciences. A substantially transformed arena within the context of the latter is the development and production of various injectable parenteral formulations. Indeed, recent decades have witnessed a rapid growth of the marketed and pipeline nanotechnology-based injectable products, which is a testimony to the remarkability of the aforementioned contribution. Adjunct to the ability of nanomaterials to deliver the incorporated payloads to many different targets of interest, nanotechnology has substantially assisted to the development of many further facets of the art. Such contributions include the enhancement of the drug solubility, development of long-acting locally and systemically injectable formulations, tuning the onset of the drug’s release through the endowment of sensitivity to various internal or external stimuli, as well as adjuvancy and immune activation, which is a desirable component for injectable vaccines and immunotherapeutic formulations. The current work seeks to provide a comprehensive review of all the abovementioned contributions, along with the most recent advances made within each domain. Furthermore, recent developments within the domains of passive and active targeting will be briefly debated.

show abstract

Development of anti-CD47 single-chain Variable Fragment Targeted Magnetic Nanoparticles for Treatment of Human Bladder Cancer

Abstract: The anti-CD47 scFv-MNP conjugate was an effective cancer cell thermotherapy tool that might pave the way for development of bionano-based targeting techniques in both early detection and treatment of cancer.

Cited by 17 publications

References 49 publications

Applications of Magnetite Nanoparticles in Cancer Immunotherapies: Present Hallmarks and Future Perspectives

Applications of Magnetite Nanoparticles in Cancer Immunotherapies: Present Hallmarks and Future Perspectives

Antibody‐Incorporated Nanomedicines for Cancer Therapy

Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art

Contact Info

Product

Resources

About